KR890000521A - 변형된 성장 인자 도메인을 갖는 조직 플라즈미노겐 활성제 동족체 - Google Patents
변형된 성장 인자 도메인을 갖는 조직 플라즈미노겐 활성제 동족체 Download PDFInfo
- Publication number
- KR890000521A KR890000521A KR1019880006717A KR880006717A KR890000521A KR 890000521 A KR890000521 A KR 890000521A KR 1019880006717 A KR1019880006717 A KR 1019880006717A KR 880006717 A KR880006717 A KR 880006717A KR 890000521 A KR890000521 A KR 890000521A
- Authority
- KR
- South Korea
- Prior art keywords
- growth factor
- homolog
- amino acid
- plasminogen activator
- factor domain
- Prior art date
Links
- 239000003102 growth factor Substances 0.000 title claims 11
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 title claims 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 title 1
- 229960000187 tissue plasminogen activator Drugs 0.000 title 1
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 claims description 16
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000001938 Plasminogen Activators Human genes 0.000 claims 5
- 108010001014 Plasminogen Activators Proteins 0.000 claims 5
- 235000001014 amino acid Nutrition 0.000 claims 5
- 229940127126 plasminogen activator Drugs 0.000 claims 5
- 102000013566 Plasminogen Human genes 0.000 claims 4
- 108010051456 Plasminogen Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 3
- 102100023804 Coagulation factor VII Human genes 0.000 claims 2
- 108010023321 Factor VII Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 229940012413 factor vii Drugs 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 101800003838 Epidermal growth factor Proteins 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 claims 1
- 101800004937 Protein C Proteins 0.000 claims 1
- 102000017975 Protein C Human genes 0.000 claims 1
- 101800001700 Saposin-D Proteins 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000593 degrading effect Effects 0.000 claims 1
- 229940116977 epidermal growth factor Drugs 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 229940012957 plasmin Drugs 0.000 claims 1
- 229960000856 protein c Drugs 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제 1 도는 암호화된 단백질의 아미노산 서열과 함께, CDNA 및 합성된 올리고-뉴클레오타이드로부터 작제된 서열을 암호화하는 프리-프로(pre-pro) t-PA를 나타낸다. 라인 위의 수는 뉴클레오타이드 위치를 언급하고 라인 아래의 수는 아미노산 위치를 언급한다.
제 2 도는 벡터 Zem99의 작제를 나타낸다.
Claims (17)
- 적어도 하나의 시스테인 잔기가 다른 아미노산으로 대치된, 천연 조직형 플라즈미노센 활성체(tissue-type plasminogen activator)가 성장 인자 도메인을 포함하는 t-PA 동족체.
- 제 1 항에 있어서, 시스테인 잔기가 천연 t-PA의 84번인 t-PA 동족체.
- 제 1 항에 있어서, 아미노산이 세린 또는 알라닌인 t-PA 동족체.
- 성장 인자 도메인, 크링글도메인 및 세린 프로테아제 도메인을 포함하며, 성장 인자 도메인은 천연 t-PA의 성장 인자 도메인과 비교하여, 실질적으로 연속적인 아미노산의 복수치환을 포함하며, 이러한 치환에 의해 플라즈마 반감기가 증가된 플라즈미노겐 활성체.
- 제 1 항에 있어서, 성장 인자 도메인이 인자 Ⅶ, 인자 Ⅸ, 단백질 C 및 표피 성장 인자로 이루어진 그룹중에서 선택된 단백질의 성장 인자 도메인으로부터의 아미노산 서열을 포함하는 플라즈미노겐 활성체.
- 제 1 항에 있어서, 성장 인자 도메인이 아미노산 서열 MEGNHLAN을 포함하는 플라즈미노겐 활성체.
- 제 1 항에 있어서, 성장 인자 도메인이 제 5 도에 제시된 단편 A 내지 N으로 이루어진 그룹중에서 선택된 성장 인자 도메인의 아미노산 서열을 포함하는 플라즈미노겐 활성체.
- 제 1 항 또는 4항에 있어서, 동족체가 절단부위의 13개의 아미노산 잔기내에서 적어도 하나의 아미노산의 치환을 추가로 포함하며, 그 결과 플라즈민에 의한 절닺ㄴ내성이 증가된 t-PA 동족체.
- 제 1 항 또는 4항에 있어서, 동족체가 두개의 크링글구조를 포함하며, 이들 중 적어도 하나가 탄수화물이 결여되어 있는 t-PA 동족체.
- 제 1 항 또는 4항에 있어서, 동족체가 플라즈미노겐으로부터 유도된 크링글구조를 포함하는 t-PA 동족체.
- 제10항에 있어서, 플라즈미노겐 크링글구조가 플라즈미노겐의 K1, K4 및 K5 크링글 도메인으로 이루어진 그룹중에서 선택되는 t-PA 동족체.
- 제11항에 있어서, 동족체가 플라즈미노겐 크링글구조의 하부에 위치한 천연 t-PA의 K2 크링글구조를 추가로 포함하는 t-PA 동족체.
- 제 4 항에 있어서, 성장 인자 도메인이 아미노산 잔기 62 및 73 사이에서 (단, 잔기 62 및 73은 제외)적어도 하나의 아미노산 치환을 포함하는 플라즈미노겐 활성체.
- 제 1 항 또는 4항의 t-PA 동족체를 암호화하는 DNA 서열.
- 프로모터에 가동 가능하게 연결된 제14항에 따른 DNA서열을 포함하는 발현 벡터로 형질 감염되어나 형질 전환된 숙주세포.
- 제 1 항 내지 12항중 어느 한 항에 있어서, 활성 치료물질로서 사용하기 위한 t-PA 동족체.
- 제 1 항 내지 12항중 어느 한 항에 있어서, 트롬빈 분해제로서 사용하기 위한 t-PA 동족체.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR97031023A KR0135314B1 (en) | 1987-06-04 | 1997-06-27 | Tissue plasminogen activator analogs having modified growth |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5806187A | 1987-06-04 | 1987-06-04 | |
| US7/058,061 | 1987-06-04 | ||
| US?07/058,061? | 1987-06-04 | ||
| US16284788A | 1988-03-02 | 1988-03-02 | |
| US?07/162,847? | 1988-03-02 | ||
| US7/162,847 | 1988-03-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR890000521A true KR890000521A (ko) | 1989-03-15 |
| KR0135427B1 KR0135427B1 (ko) | 1998-04-23 |
Family
ID=26737188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019880006717A KR0135427B1 (ko) | 1987-06-04 | 1988-06-04 | 변형된 성장인자 도메인을 갖는 조직 플라스미노겐 활성화제 동족체를 암호화하는 dna, 이를 함유하는 발현 벡터 및 이를 포함하는 숙주세포 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5403734A (ko) |
| EP (1) | EP0293936B1 (ko) |
| JP (1) | JPS6485079A (ko) |
| KR (1) | KR0135427B1 (ko) |
| AT (1) | ATE118815T1 (ko) |
| AU (1) | AU625752B2 (ko) |
| CA (1) | CA1341446C (ko) |
| DE (1) | DE3853100T2 (ko) |
| DK (1) | DK302388A (ko) |
| ES (1) | ES2069536T3 (ko) |
| FI (1) | FI101306B (ko) |
| IE (1) | IE67036B1 (ko) |
| NO (1) | NO179874C (ko) |
| NZ (1) | NZ224914A (ko) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5756093A (en) * | 1985-04-22 | 1998-05-26 | Genentech, Inc. | Tissue plasminogen activator variants |
| US5714372A (en) * | 1985-04-22 | 1998-02-03 | Genentech, Inc. | Tissue plasminogen activator variants |
| US5736134A (en) * | 1985-04-22 | 1998-04-07 | Genentech, In.C | Tissue plasminogen activator variants |
| DE3851259T2 (de) * | 1987-06-04 | 1994-12-15 | Zymogenetics Inc | Mutierter t-PA mit Kringle-Ersatz. |
| GB8815135D0 (en) * | 1988-06-24 | 1988-08-03 | British Bio Technology | Proteins & nucleic acids |
| US5714145A (en) * | 1988-09-02 | 1998-02-03 | Genentech, Inc. | Tissue plasminogen activator having zymogenic or fibrin specific properties |
| US5262170A (en) * | 1988-09-02 | 1993-11-16 | Genentech, Inc. | Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells |
| US5108901A (en) * | 1988-09-02 | 1992-04-28 | Genentech, Inc. | Tissue plasminogen activator having zymogenic or fibrin specific properties |
| US5258180A (en) * | 1988-09-02 | 1993-11-02 | Genetech, Inc. | Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment |
| US5087572A (en) * | 1989-12-01 | 1992-02-11 | Genentech, Inc. | Dna encoding human plasminogen modified at the cleavage site |
| US5190756A (en) * | 1989-12-01 | 1993-03-02 | Genentech, Inc. | Methods and materials for expression of human plasminogen variant |
| JPH0595786A (ja) * | 1991-10-07 | 1993-04-20 | Green Cross Corp:The | 変異ヒトプロウロキナーゼ |
| DE10199044I2 (de) * | 1992-06-03 | 2006-02-09 | Genentech Inc | Varianten des Gewebeplasminogenaktivators mit verbesserter Therapeutischer wirkung |
| US6706504B1 (en) | 1996-11-12 | 2004-03-16 | The Scripps Research Institute | Tissue type plasminogen activator (t-PA) variants: compositions and methods of use |
| CA2807749C (en) * | 2010-08-05 | 2023-02-28 | Council Of Scientific & Industrial Research | Protein fusion constructs possessing thrombolytic and anticoagulant properties |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL68561A (en) * | 1982-05-05 | 1991-01-31 | Genentech Inc | Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof |
| EP0125254A1 (en) * | 1982-10-28 | 1984-11-21 | Beecham Group Plc | Enzyme derivatives and their use in the treatment of thrombosis |
| DK149786A (da) * | 1985-04-04 | 1986-10-04 | Beecham Group Plc | Proteolytisk enzym |
| FR2581652B1 (fr) * | 1985-04-22 | 1989-12-22 | Genentech Inc | Nouveaux mutants de l'activateur tissulaire du plasminogene humain |
| US4916071A (en) * | 1985-08-14 | 1990-04-10 | American Home Products Corporation | Poly-kringle plasminogen activator |
| JP2527454B2 (ja) * | 1986-01-31 | 1996-08-21 | ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド | 新しい血栓溶解タンパク質 |
| US5376547A (en) * | 1987-01-30 | 1994-12-27 | American Home Products Corporation | Des-epidermal growth factor plasminogen activators |
-
1988
- 1988-06-03 ES ES88108951T patent/ES2069536T3/es not_active Expired - Lifetime
- 1988-06-03 DK DK302388A patent/DK302388A/da not_active Application Discontinuation
- 1988-06-03 EP EP88108951A patent/EP0293936B1/en not_active Expired - Lifetime
- 1988-06-03 NO NO882454A patent/NO179874C/no not_active IP Right Cessation
- 1988-06-03 AT AT88108951T patent/ATE118815T1/de not_active IP Right Cessation
- 1988-06-03 IE IE168088A patent/IE67036B1/en not_active IP Right Cessation
- 1988-06-03 DE DE3853100T patent/DE3853100T2/de not_active Expired - Fee Related
- 1988-06-03 FI FI882627A patent/FI101306B/fi active IP Right Grant
- 1988-06-04 KR KR1019880006717A patent/KR0135427B1/ko not_active IP Right Cessation
- 1988-06-04 JP JP63138233A patent/JPS6485079A/ja active Granted
- 1988-06-06 CA CA000568718A patent/CA1341446C/en not_active Expired - Fee Related
- 1988-06-06 AU AU17430/88A patent/AU625752B2/en not_active Ceased
- 1988-06-07 NZ NZ224914A patent/NZ224914A/xx unknown
-
1991
- 1991-10-15 US US07/776,854 patent/US5403734A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| KR0135427B1 (ko) | 1998-04-23 |
| AU1743088A (en) | 1988-12-08 |
| EP0293936A3 (en) | 1989-09-20 |
| JPH0448434B2 (ko) | 1992-08-06 |
| EP0293936A2 (en) | 1988-12-07 |
| JPS6485079A (en) | 1989-03-30 |
| ES2069536T3 (es) | 1995-05-16 |
| FI882627A0 (fi) | 1988-06-03 |
| NO882454L (no) | 1988-12-05 |
| NO179874C (no) | 1997-01-02 |
| CA1341446C (en) | 2003-11-18 |
| US5403734A (en) | 1995-04-04 |
| DE3853100D1 (de) | 1995-03-30 |
| NO882454D0 (no) | 1988-06-03 |
| DK302388D0 (da) | 1988-06-03 |
| FI882627A (fi) | 1988-12-05 |
| NZ224914A (en) | 1991-02-26 |
| FI101306B1 (fi) | 1998-05-29 |
| AU625752B2 (en) | 1992-07-16 |
| ATE118815T1 (de) | 1995-03-15 |
| IE67036B1 (en) | 1996-05-15 |
| IE881680L (en) | 1988-12-04 |
| FI101306B (fi) | 1998-05-29 |
| DE3853100T2 (de) | 1995-08-03 |
| DK302388A (da) | 1989-02-03 |
| NO179874B (no) | 1996-09-23 |
| EP0293936B1 (en) | 1995-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR890000521A (ko) | 변형된 성장 인자 도메인을 갖는 조직 플라즈미노겐 활성제 동족체 | |
| Masson et al. | Identification of granzyme A isolated from cytotoxic T‐lymphocyte‐granules as one of the proteases encoded by CTL‐specific genes | |
| KR880013978A (ko) | 피브린 분해 단백질 | |
| DK36991A (da) | Vaevsplasminoaktivator-(t-pa)-variant med zymogene eller fibrinspecifikke eller plasmakoagel-specifikke egenskaber, fremgangsmaade til fremstilling deraf, dna-sekvens, som koder for varianten, replicerbar udtrykkelsesvektor for denne og vaertsceller transformeret med vektoren | |
| KR890000665A (ko) | 크링글 치환이 있는 돌연변이체 t-PA | |
| Vehar et al. | Characterization studies on human melanoma cell tissue plasminogen activator | |
| Wilhelm et al. | Functional properties of the recombinant kringle-2 domain of tissue plasminogen activator produced in Escherichia coli. | |
| Lijnen et al. | In vitro fibrinolytic activity of recombinant tissue-type plasminogen activator in the plasma of various primate species | |
| Cheng et al. | Purification, characterization, and cDNA cloning of a new fibrinogenlytic venom protein, Agkisacutacin, from Agkistrodon acutus venom | |
| Stürzebecher et al. | Mapping of the catalytic site of CHO‐t‐PA and the t‐PA variant BM 06.022 by synthetic inhibitors and substrates | |
| US5977056A (en) | Treatment of thrombotic events | |
| Browne et al. | Expression of recombinant human plasminogen and aglycoplasminogen in HeLa cells | |
| US5260060A (en) | Fibrinolytic enzymes | |
| Pohl et al. | Differences between uterine and melanoma forms of tissue plasminogen activator | |
| US6869778B2 (en) | Tissue type plasminogen activator (t-PA) variants: compositions and methods of use | |
| Straight et al. | Structural and functional characterization of the inhibition of urokinase by. alpha. 2-macroglobulin | |
| FI114102B (fi) | Menetelmä trombiinin vaikutuksesta pilkkoutuvan plasminogeenianalogin valmistamiseksi | |
| Larsen et al. | Pharmacokinetics of genetically modified t-PA in rat | |
| US5688664A (en) | Thrombin activatable plasminogen analogues | |
| CA2271697C (en) | Tissue type plasminogen activator (t-pa) variants: compositions and methods of use | |
| Lijnen et al. | Biochemical and biological properties of a recombinant tissue-type plasminogen activator derived from the rat JMI-229 cell line | |
| CA2162986A1 (en) | Proteins having fibrinolytic and coagulation-inhibiting properties | |
| Verheijen et al. | Sites in tissue-type plasminogen activator involved in the interaction with fibrin, plasminogen and low molecular weight ligands | |
| Browne et al. | Protein engineering and comparative pharmacokinetic analysis of a family of novel recombinant hybrid and mutant plasminogen activators | |
| Loscalzo | Fibrinolytic therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20070109 Year of fee payment: 10 |
|
| LAPS | Lapse due to unpaid annual fee |